GUARD Consortium

COLLEAGUES AT #EAU26 Our friends from @GuardConsortium 🇪🇸Deliver another Great Informational Capsule, this time direct from #GU26 🇺🇸 We are proud to introduce our Colleague @mjuanfi81 Discussing the Presentation of: KEYNOTE-B15/EV 304 The phase 3 KEYNOTE-B15 trial evaluated perioperative enfortumab vedotin plus pembrolizumab versus standard cisplatin-based chemotherapy in 808 patients with muscle-invasive #BladderCancer eligible for cisplatin. The combination reduced recurrence or progression risk by 47% and improved pathologic complete response rates (56% vs 32.5%). Although higher-grade toxicities occurred, results suggest this regimen may improve survival and represent a potential new perioperative standard, warranting further comparative investigation. buff.ly/LIBgTVi @cdanicas @dralvaropinto @drenriquegrande @nachoduranm @DrJaVallejo @abraocantoMD @docjavip @AlvarezMa89031 @DrFelixGuerrero @BerUrologia @AnaPlatabello1 @AlvarezMa89031 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campos @Dav_Lorente @EurUrolOncol @tompowles1

Our friends from @GuardConsortium 🇪🇸Deliver another Great Informational Capsule, this time direct from #GU26 🇺🇸 We are proud to introduce our Colleague @mjuanfi81 Discussing the Presentation of: Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. In cisplatin-ineligible MIBC, phase 3 KEYNOTE-905/EV-303 showed that neoadjuvant–adjuvant enfortumab vedotin plus pembrolizumab significantly improved pCR (57.1% vs 8.6%), pathological downstaging (65.9% vs 12.6%), negative margins, and DFS (HR 0.37) versus surgery alone. Median DFS was not reached, supporting this regimen as a new standard of care. #BladderCancer @cdanicas @dralvaropinto @drenriquegrande @nachoduranm @DrJaVallejo @abraocantoMD @docjavip @AlvarezMa89031 @DrFelixGuerrero @BerUrologia @AnaPlatabello1 @AlvarezMa89031 @scocmem @OncBrothers @Helena_de_Palma @F_lopez_campos @Dav_Lorente @EurUrolOncol